Published in Gastroenterology on July 13, 2010
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol (2014) 1.51
Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther (2010) 1.24
Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. J Hepatol (2011) 1.16
LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics (2015) 1.11
Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int (2012) 1.04
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget (2014) 0.96
Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol (2014) 0.96
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol (2014) 0.94
Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol (2012) 0.90
Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer (2011) 0.89
Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res (Phila) (2011) 0.87
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.84
Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One (2011) 0.84
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci (2016) 0.84
ω3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS One (2013) 0.83
Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS One (2014) 0.83
Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells. Free Radic Biol Med (2012) 0.83
Role of adiponectin and its receptors in cancer. Cancer Biol Med (2012) 0.83
Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression. J Cancer Res Clin Oncol (2013) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract (2012) 0.82
Increased adiponectin associated with poor survival in hepatocellular carcinoma. J Gastroenterol (2013) 0.81
Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med (2016) 0.81
Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol (2014) 0.80
Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver (2016) 0.78
Regulatory role of autophagy in globular adiponectin-induced apoptosis in cancer cells. Biomol Ther (Seoul) (2014) 0.78
The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.78
Adiponectin ameliorates experimental periodontitis in diet-induced obesity mice. PLoS One (2014) 0.78
Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol (2016) 0.77
Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol (2013) 0.77
Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Mol Clin Oncol (2014) 0.77
Adiponectin inhibits murine pancreatic cancer growth. Dig Dis Sci (2014) 0.76
Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol (2016) 0.76
Adiponectin deficiency contributes to the development and progression of benign prostatic hyperplasia in obesity. Sci Rep (2017) 0.75
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clin (2015) 0.75
A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Association analysis of genetic variants of adiponectin gene and risk of pancreatic cancer. Int J Clin Exp Med (2015) 0.75
Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study. PLoS One (2016) 0.75
The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget (2017) 0.75
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
Signal transduction by the JNK group of MAP kinases. Cell (2000) 18.24
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science (1980) 13.44
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res (1982) 11.72
The stress-activated protein kinase subfamily of c-Jun kinases. Nature (1994) 11.45
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 9.79
A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 9.72
Adiponectin and adiponectin receptors. Endocr Rev (2005) 8.46
Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol (2005) 8.39
AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem (1996) 6.93
Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med (2007) 5.89
The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci (2004) 5.65
cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun (1996) 5.40
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology (2003) 5.09
Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med (2004) 4.05
The expanding TOR signaling network. Curr Opin Cell Biol (2005) 3.30
Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med (2005) 3.29
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol (2006) 3.11
The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta (2007) 2.83
Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab (2004) 2.74
Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (1996) 2.49
Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol (2007) 2.40
Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer (1994) 2.33
Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev (2001) 2.17
Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep (2003) 1.90
Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem (2005) 1.83
Adipocytokines and cancer. Physiol Res (2005) 1.67
Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res (2005) 1.64
Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl (2005) 1.37
Expanding role of AMPK in endocrinology. Trends Endocrinol Metab (2006) 1.29
Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun (2005) 1.28
Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl (2004) 1.26
Keynote review: the adipocyte as a drug discovery target. Drug Discov Today (2005) 1.24
Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology (2001) 1.19
Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol (2005) 1.07
Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res (2009) 0.93
AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation. Carcinogenesis (2008) 0.91
Obesity: an endocrine tumor? Med Hypotheses (2004) 0.90
Smoking and obesity in relation to the etiology and disease progression of prostate cancer in Japan. Int J Urol (1998) 0.88
Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res (2004) 0.85
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol (2003) 2.67
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis (2002) 2.53
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol (2008) 2.46
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol (2005) 2.32
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A (2002) 2.29
Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology (2007) 2.25
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 2.15
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol (2002) 2.05
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Validity of electronic health record-derived quality measurement for performance monitoring. J Am Med Inform Assoc (2012) 1.86
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend (2008) 1.73
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem (2002) 1.66
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann Surg Oncol (2003) 1.56
Patients with hip fracture: subgroups and their outcomes. J Am Geriatr Soc (2002) 1.52
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol (2006) 1.52
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol (2004) 1.52
Molecular classification of renal tumors by gene expression profiling. J Mol Diagn (2005) 1.52
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Hum Pathol (2009) 1.49
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem (2007) 1.48
Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). Hum Pathol (2004) 1.47
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leuk Lymphoma (2011) 1.40
Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer (2011) 1.39
Shanthi V. Sitaraman, MD, PhD: physician, scientist, educator, and humanitarian. Gastroenterology (2011) 1.39
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem (2003) 1.39
Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem (2012) 1.37
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res (2003) 1.34
Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol (2005) 1.34
Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol (2004) 1.32
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat (2003) 1.32
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res (2010) 1.29
Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol (2008) 1.28
GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One (2011) 1.26
The pivotal role of integrin β1 in metastasis of head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.25
Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology (2010) 1.23
Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest (2003) 1.22
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol (2009) 1.21
Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol (2003) 1.21
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
Epstein-Barr virus induced hepatitis: An important cause of cholestasis. Hepatol Res (2005) 1.20
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem (2003) 1.19
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol (2011) 1.19
The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol (2003) 1.17
Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer (2002) 1.16
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat (2009) 1.15
Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol (2010) 1.15
Health Care Experiences and Perceived Barriers to Health Care Access: A Qualitative Study Among African Migrants in Guangzhou, Guangdong Province, China. J Immigr Minor Health (2015) 1.13
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer (2012) 1.13
Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol (2005) 1.13
Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis (2012) 1.13
Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol (2007) 1.12
AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol (2007) 1.12
Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg (2008) 1.12
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One (2010) 1.11
Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases. Am J Surg Pathol (2008) 1.10
Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol (2006) 1.09
Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol (2003) 1.08
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem (2010) 1.08
Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem (2010) 1.07
TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol (2011) 1.07
Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology (2004) 1.06
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer (2008) 1.06
A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials. Contemp Clin Trials (2010) 1.05
Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol (2011) 1.05
Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol (2003) 1.05
Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem (2004) 1.04
Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis (2010) 1.04